Avipero Bio is aiming to Transform Cancer Treatment by Stopping Metastasis at Its Source. Avipero Bio’s unique β1-integrin modulators (AVI001, AVI002) inhibit cancer spread and extend survival and are applicable across metastatic cancers.
________________________________________
The Unmet Need
Metastatic Cancer Remains the Deadliest Stage of cancer with 82.6% of metastatic cancer patients dying within 10 months. To date, no drugs effectively prevent or reverse metastasis. There is also rising global incidence with the market expected to be valued at $158B market by 2032.
________________________________________
The Problem: The Biology of Metastasis
Current treatments fail due to multiple factors but mainly due to:
•	Tumor heterogeneity triggering uncontrolled metastasis.
•	Integrin overactivation drives invasion and treatment resistance.
•	Senescence allows metastatic cells to survive and relapse.
________________________________________
The Solution: AVI001
Avipero Bio’s First-in-Class β1-integrin modulator is unique because it:
•	Normalizes cell adhesion and restores normal growth signals.
•	Reverses senescence and blocks metastasis in vivo (60% tumor reduction).
•	Demonstrated efficacy across multiple solid tumor models.
________________________________________


AVIPERO Bio

Org chart

Teams

Offices